search
antisarscov
tanshinon
deriv
salvia
miltiorrhiza
found
specif
select
inhibitor
sarscov
pro
pl
pro
viral
cystein
proteas
literatur
search
studi
involv
seven
isol
tanshinon
hit
show
present
none
identifi
coronavir
proteas
inhibitor
identifi
isol
tanshinon
good
inhibitor
cystein
proteas
howev
activ
slightli
affect
subtl
chang
structur
target
enzym
isol
compound
act
time
depend
inhibitor
pl
pro
improv
inhibit
observ
follow
preincub
pro
detail
kinet
mechan
studi
tanshinon
except
rosmariquinon
identifi
noncompetit
enzym
isomer
inhibitor
howev
rosmariquinon
show
differ
kinet
mechan
mixedtyp
simpl
revers
slowbind
inhibit
furthermor
tanshinon
exhibit
potent
nanomolar
level
inhibitori
activ
toward
deubiquitin
ic
lm
addit
inhibit
select
compound
exert
signific
inhibitori
effect
proteas
includ
chymotrysin
papain
hiv
proteas
find
provid
potenti
inhibitor
sarscov
viral
infect
replic
abbrevi
ic
inhibitor
concentr
lead
activ
loss
k
inhibit
constant
k
app
appar
k
k
rate
constant
v
max
maximum
veloc
k
michaelismenten
constant
k
ob
appar
firstord
rate
constant
transit
v
v
v
initi
veloc
v
steadyst
rate
sar
sever
acut
respiratori
syndrom
cov
coronaviru
sever
acut
respiratori
syndrom
sar
lifethreaten
form
atyp
pneumonia
first
occur
guandong
provinc
china
rapidli
spread
sever
countri
part
world
fatal
rate
sar
rather
high
first
wave
sar
outbreak
approxim
peopl
worldwid
affect
die
reemerg
sar
south
china
report
decemb
spring
instanc
necessarili
indic
anoth
global
outbreak
illustr
need
continu
studi
viru
develop
appropri
therapeut
treatment
sarscov
singlestrand
positivestrand
rna
viru
genom
structur
compris
replicas
structur
region
encod
two
overlap
polyprotein
ppla
kda
pplab
kda
polypeptid
releas
polyprotein
extens
proteolyt
process
primarili
perform
viral
encod
chymotrypsinlik
proteas
pro
also
call
main
proteas
pro
addit
cleavag
perform
viral
papainlik
proteas
pl
pro
essenti
role
viral
replic
proteas
recogn
attract
target
develop
antisar
therapeut
surprisingli
numer
studi
relat
develop
sarscov
pro
inhibitor
alreadi
report
activ
site
sarscov
pro
contain
constitut
catalyt
dyad
cystein
function
common
nucleophil
proteolyt
process
until
inhibitor
studi
focus
sarscov
pro
util
synthet
peptidyl
librari
natur
deriv
librari
exampl
peptideder
inhibitor
includ
diol
quinolinecarboxyl
acid
anilid
natur
deriv
inhibitor
includ
quinonemethid
triterpen
biflavonoid
amentoflavon
includ
screen
natur
product
activ
pro
contrast
structur
function
studi
focus
pl
pro
far
less
numer
establish
import
role
pl
pro
beyond
viral
peptid
cleavag
includ
deubiquitin
deisgyl
involv
viru
evas
innat
respons
locat
polypeptid
undergo
selfcleavag
three
site
polypeptid
catalyt
triad
broad
rang
optimum
ph
valu
characterist
papainlik
cystein
proteas
date
small
number
inhibitor
pl
pro
studi
includ
molecul
identifi
highthroughput
screen
thiopurin
analog
benzamid
deriv
noncovel
inhibitor
despit
numer
biochem
strucutr
inhibitordevelop
studi
direct
pro
pl
pro
potent
antivir
directli
target
proteas
yet
develop
search
sarscov
pro
pl
pro
inhibitor
natur
sourc
found
lipophil
fraction
salvia
miltiorrhiza
ethanol
extract
possess
inhibitori
activ
proteas
salvia
miltiorrhiza
root
laminacea
widli
use
china
korea
japan
asian
countri
treat
coronay
heart
diseas
paricularli
angina
pectori
myocardi
infarct
two
class
major
activ
compound
miltiorrhiza
name
lipophil
tanshinon
hydrophil
salvianol
acid
compound
found
exhibit
antioxid
antiinflamm
antivir
properti
huang
cowork
isol
two
potent
nontox
intergras
inhibitor
plant
salvianolid
acid
deriv
lithosperm
acid
lithosperm
acid
b
best
knowledg
applic
inhibit
sarscov
main
cystein
proteas
never
report
studi
conduct
biolog
evalu
seven
isol
tanshinon
miltiorrhiza
investig
inhibit
select
constitu
sarscov
pro
pl
pro
studi
synthes
express
escherichia
coli
e
coli
pro
pl
pro
well
open
read
frame
orf
contain
catalyt
domain
inhibitor
screen
proteas
use
fluoresc
peptid
substrat
steadyst
inhibit
paramet
effect
inhibitor
evalu
mode
action
inhibitor
investig
kinet
assay
function
time
expos
inhibitor
knowledg
structur
first
show
sar
coronavir
cystein
proteas
pro
pl
pro
deubiquitin
dub
enzym
activ
character
quinoid
suggest
provid
good
scaffold
optim
drug
develop
sar
numer
function
requisit
role
sarscov
cystein
proteas
pro
pl
pro
viral
replic
pathogenesi
suggest
may
serv
attract
target
antivir
drug
ultim
goal
develop
natur
deriv
sar
viral
cystein
proteas
inhibitor
use
antisar
drug
first
step
toward
goal
express
sarscov
pro
e
coli
codonplusril
cell
purifi
protein
homogen
evalu
fretbas
peptid
cleavag
assay
measur
kinet
activ
sarscov
pro
purif
consist
combin
hydrophob
interact
anion
exchang
chromatographi
result
purifi
singl
protein
weight
approxim
kda
peptid
substrat
util
knstlqsglrke
label
dabcyl
edan
also
express
purifi
sarscov
pl
pro
kda
e
coli
codonplusril
pl
pro
locat
within
cleav
boundari
use
consensu
motif
lxgg
therefor
identifi
potenti
inhibitor
pl
pro
use
sensit
fluoresc
screen
develop
initi
work
use
commerci
avail
peptid
substrat
repres
ctermin
residu
lxgg
ctermin
amc
fluorogen
report
group
studi
sarscov
cystein
proteas
inhibitori
activ
evalu
express
protein
substrat
follow
gener
procedur
previous
describ
inhibit
proteas
slowli
increas
increas
concentr
correspond
compound
ic
valu
compound
express
abil
inhibit
catalyt
activ
proteas
calcul
fit
doserespons
curv
logist
deriv
equat
preliminari
studi
confirm
sarscov
pro
pl
pro
inhibitori
activ
ethanol
extract
salvia
miltiorrhiza
ethanol
extract
exhibit
inhibit
pro
pl
pro
respect
lgml
main
constitu
plant
number
tanshinon
includ
lipophil
compound
diterpen
quinolon
hydrophil
phenol
salvianol
acid
deriv
partit
crude
extract
fraction
organ
solvent
nhexan
ethyl
acet
h
differ
polar
among
partit
fraction
ethanol
extract
nhexanesolubl
fraction
show
notic
proteas
inhibit
activ
activityguid
fraction
lipophil
nhexan
fraction
yield
seven
tanshinon
purifi
silica
gel
sephadex
octadecylfunction
silica
gel
delin
isol
tanshinon
identifi
known
speci
tanshinon
iia
tanshinon
iib
methyl
tanshinon
cryptotanshinon
tanshinon
dihydrotanshinon
rosmariquinon
analysi
spectroscop
data
comparison
previou
studi
fig
effect
isol
tanshinon
activ
sarscov
pro
isol
tanshinon
evalu
inhous
sarscov
pro
pl
pro
inhibitori
activ
turn
allow
us
develop
new
class
inhibitor
increas
select
result
inhibit
studi
proteas
express
ic
valu
report
tabl
first
inhibitori
potenc
capac
tanshinon
toward
sarscov
pro
investig
sarscov
pro
inhibitori
activ
assay
follow
proteolysi
fluorogen
substrat
presenc
absenc
test
compound
describ
previou
studi
shown
tabl
isol
tanshinon
examin
apart
cryptotanshinon
exhibit
dosedepend
inhibitori
effect
pro
fig
howev
compound
timedepend
inhibit
profil
improv
inhibitori
activ
observ
preincub
inhibitor
pro
salvianol
acid
b
repres
bioactiv
compound
hydrophil
fraction
show
signific
inhibitori
effect
lm
found
activ
compound
rang
lm
pro
importantli
dihydrotanshinon
show
extrem
high
inhibit
ic
valu
lm
addit
activ
slightli
affect
subtl
chang
structur
identifi
activ
inhibitori
pharmacophor
structurefunct
relationship
studi
carri
initi
presenc
naphthalen
diterpen
quinolon
backbon
appear
import
activ
comparison
presenc
dimethyl
tetranaphthalen
exampl
contain
dimethyl
tetranaphthalen
ic
valu
lm
respect
contain
naphthalen
show
ic
valu
lm
subsequ
compar
seri
tanshinon
ii
analog
found
introduct
dihydrofuran
moieti
are
group
decreas
inhibitori
activ
contrast
result
obtain
inhibitor
furan
moieti
hydroxymethyl
group
dring
deriv
exhibit
improv
enzym
inhibitori
activ
ic
valu
lm
correspond
methyl
ester
dring
deriv
also
show
similar
potenc
enhanc
ic
lm
contrast
dihydrofuran
moieti
tanshinon
ic
lm
turn
potent
furan
ic
lm
within
seri
tanshinon
analog
compound
test
sarscov
pl
pro
use
continu
fluorometr
assay
increas
fluoresc
k
ex
nm
k
em
nm
monitor
use
spectrofluorimet
initi
rate
calcul
first
min
progress
curv
interestingli
isol
compound
show
timedepend
inhibitori
effect
pl
pro
activ
first
report
natur
deriv
inhibitor
pl
pro
observ
data
present
tabl
figur
isol
compound
miltiorrhiza
preincub
min
show
inhibit
without
incub
tanshinon
show
increas
inhibit
enzymat
activ
pl
ompar
pro
nanomolar
micromolar
rang
evidenc
pl
pro
inhibit
dimethyl
tetrahydronaphthalen
structur
show
potent
inhibitori
respons
naphthalen
chymotyp
isol
tanshinon
cryptotanshinon
display
potent
inhibitori
activ
ic
lm
compar
seri
tanshinon
ii
deriv
shown
furan
moieti
are
show
improv
inhibit
pl
pro
result
unexpect
increas
inhibit
pro
compar
tanshinon
iia
ic
lm
show
twofold
lower
inhibit
effect
cryptotanshinon
similar
trend
also
observ
tanshinon
ic
lm
dihydrotanshinon
ic
lm
show
respect
similar
inhibitori
activ
similar
are
structur
tanshinon
ii
analog
ic
lm
ic
lm
suggest
presenc
hydroxymethyl
methyl
ester
dring
weak
effect
inhibit
potenc
interestingli
abietan
analog
rosmariquinon
display
signific
activ
sarscov
cystein
proteas
ic
valu
lm
abietan
skeleton
structur
relat
tanshinon
activ
noteworthi
suggest
research
import
lead
compound
need
investig
inhibit
mechan
time
depend
inhibit
proteolysi
argleuargglyglyamc
rlrggamc
inhibitor
subsequ
probe
reaction
progress
curv
presenc
vari
concentr
isol
tanshinon
illustr
taken
ensembl
residu
enzym
activ
decreas
function
pl
pro
tanshinon
incub
time
figur
repres
compound
show
clear
timeand
concentrationdepend
approach
steadyst
curv
downward
characterist
slowbind
inhibit
kinet
fig
fig
pl
pro
inhibitor
manifest
relationship
enzym
activ
slowbind
inhibit
mechan
investig
preincub
enzym
inhibitor
follow
measur
initi
veloc
substrat
proteolysi
function
preincub
time
increas
concentr
compound
led
decreas
initi
veloc
v
steadyst
rate
v
progress
curv
obtain
use
variou
concentr
inhibitor
fit
eq
determin
v
v
k
ob
plot
repres
relationship
k
ob
possibl
inhibit
mode
simpl
revers
slowbind
enzym
isomer
mechanismbas
inhibit
determin
kinet
profil
play
kinet
paramet
k
k
k
k
k
app
deriv
plot
fit
result
tabl
result
inhibitor
fit
slowbind
eq
illustr
hyperbol
depend
k
ob
concentr
pl
pro
tanshinon
except
rosmariquinon
base
kinet
observ
believ
reaction
undergo
follow
kinet
mechan
fig
fig
hyperbol
depend
observ
inhibitor
suggest
inhibit
pl
pro
rapid
format
enzym
complex
slowli
isomer
modifi
enzym
complex
e
fig
expect
sustain
inhibitori
process
longer
convent
inhibitor
k
higher
k
interestingli
abietanecontain
structur
rosmariquinon
found
isol
compound
shown
time
depend
k
ob
exhibit
linear
depend
inhibitor
concentr
depict
figur
thu
result
prove
abietan
type
compound
miltiorrhiza
inhibit
sarscov
pl
pro
simpl
revers
slowbind
model
accord
data
yield
analysi
eq
list
tabl
conclus
suggest
fourring
inhibitor
may
differ
bind
mode
threering
inhibitor
addit
compound
repres
new
class
sarscov
pl
pro
inhibitor
knowledg
first
natur
deriv
potent
timedepend
inhibitor
enzym
next
studi
kinet
mechan
interact
inhibitor
proteas
pro
pl
pro
enzymat
activ
measur
seri
substrat
concentr
variou
inhibitor
concentr
inhibit
data
global
fit
possibl
kinet
model
result
kinet
analysi
found
miltiorrhizaderiv
proteas
inhibitor
could
divid
two
class
base
upon
mode
inhibit
class
could
also
divid
basi
structur
target
enzym
isol
tanshinon
exhibit
noncompetit
inhibit
characterist
toward
pro
see
supplementari
data
fig
fig
case
pl
pro
kinet
plot
fourring
tanshinon
also
show
noncompetit
inhibit
kinet
see
supplementari
data
fig
fig
threering
compound
except
rule
illustr
repres
figur
inhibit
kinet
analyz
dixon
plot
show
compound
noncompetit
mechan
dixon
plot
versu
result
famili
straight
line
xaxi
intercept
illustr
substrat
concentr
compound
display
mix
type
inhibit
sarscov
pl
pro
shown
dixon
plot
fig
dixon
plot
versu
result
famili
straight
line
axi
intercept
kinet
mechan
support
infer
drawn
timedepend
assay
reveal
import
role
sarscov
pl
pro
inhibit
mode
notabl
slowbind
enzym
inhibitor
act
competit
inhibitor
although
possibl
interact
enzym
competit
noncompetit
uncompetit
inhibitioin
patten
despit
similar
molecular
size
function
diterpen
quinolon
tanshinon
deriv
inhibit
sarscov
pl
pro
isomer
slowbind
mode
wherea
abietan
type
deriv
activ
pl
pro
simpl
slowbind
mode
pl
pro
locat
within
cleav
boundari
use
consensu
motif
lxgg
along
consensu
cleavag
sequenc
cellular
deubiquitin
dub
enzym
model
studi
crystal
structur
reveal
orrel
sarscov
pl
pro
herp
viru
associ
ubiquitinspecif
proteas
indic
potenti
dub
activ
observ
vitro
cleavag
assay
becom
clear
deubiquitin
may
import
implic
viral
replic
pathogenesi
experiment
confirm
predict
dub
activ
isol
cystein
proteas
inhibitor
observ
dub
activ
vitro
character
tabl
date
potent
select
chemic
compound
avail
inhibit
dub
henc
biolog
consequ
inhibit
dub
clear
moment
moreov
function
dub
activ
pl
pro
vivo
unknown
ident
vivo
cellular
substrat
thu
investig
necessari
determin
specif
inhibit
tanshinon
pl
pro
dub
interact
studi
need
measur
cleavag
ubiquitinlik
protein
interferon
ifn
induc
kda
protein
protein
suggest
deisgyl
pl
pro
mechan
sarscov
inactiv
ifnabinduc
innat
immun
respons
subsequ
compound
also
evalu
variou
proteas
studi
select
detect
inhibit
proteas
test
observ
tabl
nevertheless
detect
inhibit
observ
concentr
indic
tanshinon
interest
select
viral
proteas
could
prove
viabl
lead
proteolyt
enzym
current
mani
report
ration
design
librarybas
screen
identifi
sever
small
molecul
act
potent
inhibitor
replic
sarscov
also
hiv
proteas
inhibitor
contrast
tanshinonesbas
viral
proteas
inhibitor
show
signific
hiv
proteas
inhibit
effect
sarscov
caus
agent
sever
acut
respiratori
syndrom
sar
viral
encod
proteas
pro
papainlik
proteas
pl
pro
presum
critic
viral
replic
sarscov
studi
focus
natur
deriv
tanshinon
inhibitori
activ
proteas
compound
abund
lipophil
fraction
miltiorrhiza
extract
best
knowledg
first
report
describ
inhibitori
effect
tanshinon
sarscov
main
proteas
isol
compound
show
mark
inhibitori
activ
pro
pl
pro
activ
significantli
affect
subtl
chang
structur
ic
valu
inhibitor
although
higher
peptidederiv
small
molecul
viral
cystein
proteas
inhibitor
nonetheless
low
micromolar
rang
particular
seven
compound
exert
signific
pl
pro
inhibitori
activ
rang
lm
inhibit
improv
preincub
pl
pro
addit
detail
kinet
mechan
analysi
speci
unveil
exhibit
slowbind
inhibit
enzym
isomeris
noncompetit
inhibitor
except
compound
interestingli
introduct
threering
abietan
analog
show
simpl
revers
slowbind
inhibitor
mixedtyp
inhibit
furthermor
potenti
usag
develop
novel
inhibitor
pl
pro
cellular
deubitquitin
enzym
dub
base
isol
compound
discuss
studi
tanshinon
tanshinon
show
potent
dub
activ
ic
valu
lm
result
studi
warrant
investig
examin
effect
natur
product
inhibit
sarscov
effort
advanc
initi
sought
identifi
novel
small
molecul
specif
target
sarscov
h
c
nmr
data
obtain
mhz
ftnmr
spectromet
jeol
ltd
japan
spectromet
cdcl
tetramethylsilan
tm
intern
standard
melt
point
measur
thoma
scientif
capillari
melt
point
apparatu
electrontherm
uk
uncorrect
electrospray
ioniz
esi
mass
spectra
scan
use
ei
neg
posit
mode
esquir
mass
spectromet
bruker
daltonik
gmbh
germani
reagent
grade
chemic
purchas
sigma
chemic
co
st
loui
mo
usa
purif
monitor
commerci
avail
glassback
merck
precoat
tlc
plate
visual
uv
illumin
nm
andor
nm
stain
h
solut
silica
gel
mesh
merck
odsa
nm
mm
ymc
sephadex
pharmacia
biotech
ab
uppsala
sweden
use
column
chromatographi
dri
root
miltiorrhiza
kg
extract
etoh
l
week
room
temperatur
crude
extract
filter
evapor
reduc
pressur
extract
g
obtain
brown
residu
suspend
distil
water
l
suspend
extract
partit
organ
solvent
differ
polar
nhexan
ethyl
acet
distil
water
l
respect
consequ
obtain
four
fraction
nhexan
g
ethyl
acet
g
distil
water
g
lipophil
nhexan
fraction
g
subject
silica
gel
column
chromatographi
use
gradient
mix
solvent
nhexaneethyl
acet
achiev
five
fraction
fraction
g
chromatographi
sephadex
chromatographi
use
methanol
solvent
give
three
subfract
subfract
g
purifi
prepar
hplc
use
isocrat
system
acetonitril
distil
water
give
compound
mg
subfract
g
purifi
prepar
hplc
use
isocrat
system
acetonitriledistil
water
give
compound
mg
mg
subfract
g
subject
revers
column
chromatographi
use
gradient
mix
solvent
methanoldistil
water
afford
compound
mg
fraction
g
chromatograph
silica
gel
column
chromatographi
use
mix
solvent
nhexaneethyl
acet
achiev
five
subfract
compound
mg
mg
obtain
revers
column
chromatographi
use
mix
solvent
methanoldistil
water
subfract
g
compound
mg
chromatographi
revers
column
chromatographi
use
mix
solvent
methanoldistil
water
purifi
subfract
g
two
gene
encod
proteas
pl
proteas
sarscov
synthes
base
sequenc
report
sun
et
al
han
et
al
synthes
gene
insert
clone
site
novagen
madison
wi
usa
contain
histidinetag
cterminu
e
coli
codonplusril
cell
stratagen
la
jolla
ca
usa
contain
construct
plasmid
grown
luriabertani
broth
medium
contain
lgml
ampicillin
absorb
nm
induc
mm
isopropyl
bdthiogalactopyranosid
h
collect
centrifug
cell
suspend
buffer
mm
sodium
phosphat
mm
nacl
mm
imidazol
triton
ph
suspend
cell
sonic
centrifug
min
supernat
load
nisepharos
column
equilibr
buffer
column
wash
buffer
sampl
protein
elut
mm
imidazol
elut
buffer
chang
mm
trishcl
buffer
ph
mm
dithiothreitol
protein
concentr
use
amicon
ultra
filter
molecular
weight
cutoff
millipor
billerica
usa
enzym
concentr
determin
absorb
nm
purifi
protein
store
use
assay
inhibitori
effect
prepar
sampl
sarscov
pro
measur
use
fret
method
develop
describ
previous
group
assay
fluorogen
peptid
dabcylknstlqsglrkeedan
anygen
co
republ
korea
use
substrat
enhanc
fluoresc
due
cleavag
substrat
catalyz
proteas
measur
nm
excit
nm
use
fluoresc
plate
reader
bioteck
instrument
inc
usa
ic
valu
isol
compound
measur
reaction
mixtur
contain
lgml
pro
final
concentr
lg
test
compound
lm
lm
fluorogen
peptid
substrat
mm
bistri
buffer
ph
reaction
run
min
continu
monitor
fluoresc
initi
veloc
inhibit
reaction
plot
differ
concentr
inhibitor
obtain
ic
valu
properli
fit
data
accord
analysi
method
previous
report
inhibit
assay
first
optim
inhibit
assay
first
optim
plate
format
establish
suitabl
assay
condit
incub
time
fluorogen
peptid
substrat
argleuargglyglyamc
rlrggamc
purchas
bachem
bioscienc
enhanc
fluoresc
emiss
upon
substrat
cleavag
monitor
excit
emiss
wavelength
nm
respect
spectramax
multimod
reader
molecular
devic
co
usa
reaction
mixtur
contain
nm
pl
pro
mm
trishcl
buffer
ph
total
volum
addit
lm
substrat
reaction
mixtur
increas
fluoresc
nm
continu
monitor
inhibit
studi
nm
pl
pro
lm
individu
compound
mix
substrat
lm
fluoresc
intens
monitor
studi
kinet
pro
activ
variou
concentr
fluorogen
peptid
substrat
ad
pro
reaction
buffer
kinetin
studi
sarspl
pro
use
rlrggamc
substrat
data
acquisit
initi
within
min
reaction
monitor
continu
everi
min
h
studi
kinet
pro
pl
pro
inhibit
compound
variou
concentr
compound
ad
pro
pl
pro
assay
buffer
contain
predetermin
substrat
like
order
kinet
trial
data
acquisit
initi
within
min
reaction
monitor
continu
everi
min
h
reaction
run
least
triplic
result
present
mean
sd
timedepend
assay
progress
curv
carri
use
predetermin
recombin
proteas
substrat
optim
buffer
enzym
activ
measur
continu
min
spectromet
determin
kinet
paramet
associ
time
depend
inhibit
proteas
progress
curv
obtain
sever
inhibitor
concentr
use
fix
substrat
concentr
data
analyz
use
nonlinear
regress
program
simga
plot
spcc
inc
chicago
il
find
individu
paramet
curv
v
initi
veloc
v
steadyst
veloc
k
ob
appar
firstord
rate
constant
transit
v
v
k
app
appar
k
accord
follow
equat
v
v
ob
ob
k
ob
k
app
deubiquitin
assay
purifi
pl
pro
nm
mix
fix
compound
concentr
lm
substrat
ubiquitinamc
enzo
life
scienc
inc
usa
ad
mm
trishcl
buffer
ph
assay
perform
plate
format
enzym
activ
determin
monitor
enhanc
fluoresc
emiss
upon
substrat
cleavag
excit
emiss
wavelength
nm
respect
spectramax
multimod
reader
molecular
devic
co
usa
substrat
concentr
nm
releas
amc
measur
manner
ic
measur
describ
chymotrypsin
activ
evalu
accord
method
describ
francisco
et
al
btee
product
benzoyltyrosin
measur
monitor
absorb
nm
everi
min
papain
solut
mm
sodium
phosphat
ph
incub
variou
concentr
compound
min
mm
bapna
nabenzoyldlargininepnitroanilid
ad
increas
absorb
nm
time
monitor
hiv
proteas
assay
kit
proteas
purchas
anaspec
inc
usa
proteas
assay
buffer
preincub
compound
min
solut
mix
fret
substrat
fluoresc
intens
measur
time
exem
nm
